Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Net Income towards Common Stockholders (2023 - 2025)

Historic Net Income towards Common Stockholders for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$35.3 million.

  • Inhibrx Biosciences' Net Income towards Common Stockholders rose 1962.43% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$155.1 million, marking a year-over-year decrease of 10943.65%. This contributed to the annual value of $1.7 billion for FY2024, which is 80395.57% up from last year.
  • Latest data reveals that Inhibrx Biosciences reported Net Income towards Common Stockholders of -$35.3 million as of Q3 2025, which was up 1962.43% from -$28.7 million recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year Net Income towards Common Stockholders high stood at $1.9 billion for Q2 2024, and its period low was -$92.0 million during Q4 2023.
  • In the last 3 years, Inhibrx Biosciences' Net Income towards Common Stockholders had a median value of -$45.5 million in 2023 and averaged $139.0 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 404884.6% in 2024, then plummeted by 10154.22% in 2025.
  • Inhibrx Biosciences' Net Income towards Common Stockholders (Quarter) stood at -$92.0 million in 2023, then soared by 47.96% to -$47.9 million in 2024, then grew by 26.34% to -$35.3 million in 2025.
  • Its last three reported values are -$35.3 million in Q3 2025, -$28.7 million for Q2 2025, and -$43.3 million during Q1 2025.